Lipoprotein(a) in nephrological patients (Q30236043)

15 October 2017

1 reference

29 May 2020

Lipoprotein(a) in nephrological patients (English)

1 reference

15 October 2017

0 references

cardiovascular disease

1 reference

19 November 2019

1 reference

8 August 2019

1 reference

29 May 2020

1 reference

19 November 2019

Bernd Hohenstein

1

1 reference

15 October 2017

8 February 2017

1 reference

PMCID

5352768

Clinical research in cardiology supplements

15 October 2017

1 March 2017

5 references

24 March 2019

17 June 2019

8 August 2019

19 November 2019

29 May 2020

6 references

15 October 2017

24 March 2019

17 June 2019

8 August 2019

19 November 2019

29 May 2020

12

1 reference

15 October 2017

27-30

1 reference

15 October 2017

Suppl 1

1 reference

Creative Commons Attribution 4.0 International

15 October 2017

4 references

24 March 2019

17 June 2019

8 August 2019

on focus list of Wikimedia project

19 November 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Causes and consequences of lipoprotein(a) abnormalities in kidney disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Mechanisms and treatment of extraosseous calcification in chronic kidney disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Lipoprotein(a) accelerates atherosclerosis in uremic mice.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5352768

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

3 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11789-017-0086-Z

Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11789-017-0086-Z

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11789-017-0086-Z

High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11789-017-0086-Z

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11789-017-0086-Z

Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28181057

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the E

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28181057

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11789-017-0086-Z

1 reference

15 October 2017

1 reference

15 October 2017

1 reference

PMCID

5352768